Idorsia And J&J Hypertension Drug Edges Closer To An Uncertain Market
Executive Summary
The partners released positive data from a Phase III study of their resistant hypertension drug candidate, aprocitentan, and have already started talks with regulators, but its commercial prospects remain uncertain.
You may also be interested in...
Seven Potential Blockbuster Approvals To Look Out For In 2023
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
Seven Potential Blockbuster Approvals To Look Out For In 2023
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
Canny Clozel Gets Another $230m From J&J For Idorsia Hypertension Drug
Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.